Silence Therapeutics (SLN) Return on Capital Employed (2024 - 2026)

Silence Therapeutics has disclosed Return on Capital Employed across 3 years of filings, most recently posting 8.4% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 8.4%, up 4091.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.4% (up 4091.0% YoY), and the FY2025 annual result was 14.44%, up 2947.0% from the prior year.
• Return on Capital Employed came in at 8.4% for Q1 2026 at Silence Therapeutics, up from 17.65% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 8.4% in Q1 2026 to a low of 59.85% in Q3 2025.
• The 3-year median for Return on Capital Employed is 46.84% (2025), against an average of 38.93%.
• Across the five-year window, Return on Capital Employed jumped 2672 bps in 2025 and soared 4091 bps in 2026, its largest moves.
• Silence Therapeutics' Return on Capital Employed stood at 44.37% in 2024, then surged by 60 bps to 17.65% in 2025, then jumped by 52 bps to 8.4% in 2026.
• The last three Return on Capital Employed figures came in at 8.4% (Q1 2026), 17.65% (Q4 2025), and 59.85% (Q3 2025), per Business Quant data.